Biospherics acquires worldwide patent privileges to Dtagatose from UKRF Spherix Incorporated.

Biospherics acquires worldwide patent privileges to Dtagatose from UKRF Spherix Incorporated , an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and suppliers of regulatory and specialized consulting services to meals, product, biotechnology and pharmaceutical businesses, announced that its wholly-owned subsidiary today, Biospherics Included, has signed a permit contract with the University of Kentucky Study Foundation . The contract gives Biospherics the world-wide rights to worldwide patents filed with respect to UKRF for Dtagatose as a lipid-decreasing agent for avoidance and treatment of atherosclerosis, hypertriglyceridemia, and related dyslipidemias read article .